In adults with type 2 diabetes and overweight, liraglutide added to metformin reduced epicardial fat thickness at 3 and 6 months, and metformin alone did not.
In plain wordsIn adults with type 2 diabetes and overweight, adding liraglutide to metformin reduced fat around the heart; metformin alone did not.
- Peptide
- Liraglutide
- Outcome
- DecreaseEpicardial adipose tissue thickness
- Study
n = 54
- Comparator
- Metformin
- Outcome group
- Body weight · Cardiovascular
- Studied dose
- up to 1.8 mg once daily · subcutaneous · 6 monthsAs given in this study (human).
Measurements
- EAT thickness
- −29%
- 3 months
- EAT thickness
- −36%
- 6 months
Source sentences
In the liraglutide group, EAT decreased from 9.6 ± 2 to 6.8 ± 1.5 and 6.2 ± 1.5 mm (P < 0.001), accounting for a -29% and -36% of reduction at 3 and 6 months, respectively, whereas there was no EAT reduction in the metformin group; BMI and hemoglobinA1c improved only in the liraglutide group after 6 months.
2 context sentences(design, population, supporting numbers)
To test the hypothesis, a 6-month randomized, open-label, controlled study was performed in 95 type 2 diabetic subjects with body mass index (BMI) ≥27 kg/m2 and hemoglobinA1c ≤8% on metformin monotherapy.
Individuals were randomized in two groups to receive additional liraglutide up to 1.8 mg s.c. once daily (n = 54) or to remain on metformin up to 1,000 mg twice daily (n = 41).